Q-omics provides the consensus-scored GNG4 profile across patient tissues and cancer cell-line models. GNG4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GNG4 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, GNG4 RNA expression shows 18,999 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where GNG4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNG4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNG4 survival associations across molecular data types. GNG4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNG4 RNA expression–survival associations across cancer types. High GNG4 expression shows unfavorable associations in KIRP, ACC, MESO, KIRC, BLCA and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GNG4 RNA expression.
This table summarizes GNG4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GNG4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNG4 shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, COAD, LUSC and BRCA. The KIRC box plot shows higher GNG4 RNA expression in normal versus tumor tissue (log2 FC = −0.484, t-test p < 0.001).
This table shows molecular features associated with GNG4 in patient tissues and cancer cell lines. In patient samples, GNG4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GNG4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
